Related references
Note: Only part of the references are listed.Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid
M. A. Dimopoulos et al.
ANNALS OF ONCOLOGY (2009)
Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan
C. I. Ripamonti et al.
ANNALS OF ONCOLOGY (2009)
Synergistic effect of bisphosphonate and docetaxel on the growth of bone metastasis in an animal model of established metastatic bone disease
E. R. van Beek et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro
Johanna Raikkonen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model
Kazutaka Koto et al.
CANCER LETTERS (2009)
Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells
B. Karabulut et al.
CELL BIOLOGY INTERNATIONAL (2009)
Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells
Monica Marra et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Efficient Killing of Human Colon Cancer Stem Cells by gamma delta T Lymphocytes
Matilde Todaro et al.
JOURNAL OF IMMUNOLOGY (2009)
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Michael Gnant et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review
Ingo J. Diel et al.
SUPPORTIVE CARE IN CANCER (2009)
The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis
Lilian Sewing et al.
APOPTOSIS (2008)
Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages
Panagiotis Tsagozis et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo
Penelope D. Ottewell et al.
CLINICAL CANCER RESEARCH (2008)
Biodistribution and plasma protein binding of zoledronic acid
H. Markus Weiss et al.
DRUG METABOLISM AND DISPOSITION (2008)
Molecular and preclinical models enhancing anti-tumour activity of zoledronic acid
M. Marra et al.
EJC SUPPLEMENTS (2008)
Aminobisphosphonate-activated γδ T cells in immunotherapy of cancer:: doubts no more
Nadia Caccamo et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
Design, Synthesis, and Biological Evaluation of Novel Aminobisphosphonates Possessing an in Vivo Antitumor Activity Through a γδ-T Lymphocytes-Mediated Activation Mechanism
Danicle Simoni et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Inhibition of oral mucosal cell wound healing by bisphosphonates
Regina Landesberg et al.
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2008)
Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer
Penelope D. Ottewell et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Caspase-2 is required for cell death induced by cytoskeletal disruption
L. H. Ho et al.
ONCOGENE (2008)
RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid
Todd M. Morgan et al.
PROSTATE (2008)
Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC)
Joseph G. Kattan et al.
INVESTIGATIONAL NEW DRUGS (2008)
High-content assay to study protein prenylation
Marjo Simonen et al.
JOURNAL OF BIOMOLECULAR SCREENING (2008)
A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients
F. Jadu et al.
ANNALS OF ONCOLOGY (2007)
Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw:: Is there a diverse relationship of amino- and non-aminobisphosphonates?
Ingo J. Diel et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Zoledronic acid-induced IPP/ApppI production in vivo
Hannu Monkkonen et al.
LIFE SCIENCES (2007)
Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients
Daniele Santini et al.
CLINICAL CANCER RESEARCH (2007)
Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer
Francesco Dieli et al.
CANCER RESEARCH (2007)
Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer
W. C. M. Duivenvoorden et al.
BRITISH JOURNAL OF CANCER (2007)
Altered macrophage differentiation and immune dysfunction in tumor development
Antonio Sica et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
R115777 (Zarnestra®)/Zoledronic acid (Zometa®) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation
Michele Caraglia et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2007)
Zoledronate inhibits αvβ3 and αvβ5 integrin cell surface expression in endothelial cells
A. Bellahcene et al.
ENDOTHELIUM-JOURNAL OF ENDOTHELIAL CELL RESEARCH (2007)
Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status
B. Ory et al.
MOLECULAR PHARMACOLOGY (2007)
The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer
Claire Morgan et al.
ACTA ONCOLOGICA (2007)
Antitumor effects of aminobisphosphonates on renal cell carcinoma cell lines
Hardev Pandha et al.
JOURNAL OF UROLOGY (2006)
Emerging anti-cancer molecular mechanisms of aminobisphosphonates
M Caraglia et al.
ENDOCRINE-RELATED CANCER (2006)
Mechanisms of Disease: preclinical reports of antineoplastic synergistic action of bisphosphonates
Daniele Santini et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid
A Ullén et al.
ACTA ONCOLOGICA (2005)
Cytotoxic effects of γδ T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy
K Sato et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer
SJ Kim et al.
CANCER RESEARCH (2005)
Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients
B Vincenzi et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2005)
Modulation of TNF-α gene expression by IFN-γ and pamidronate in murine macrophages:: regulation by STAT1-dependent pathways
K Takagi et al.
JOURNAL OF IMMUNOLOGY (2005)
Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients
G Ferretti et al.
ONCOLOGY (2005)
The farnesyl transferase inhibitor R115777 (Zarnestra®) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa®) and Pamidronate
M Caraglia et al.
ONCOGENE (2004)
Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer
D Vordos et al.
BJU INTERNATIONAL (2004)
An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis
E Giraudo et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
From molds and macrophages to mevalonate: A decade of progress in understanding the molecular mode of action of bisphosphonates
MJ Rogers
CALCIFIED TISSUE INTERNATIONAL (2004)
Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model
T Hiraga et al.
CLINICAL CANCER RESEARCH (2004)
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion
LS Rosen et al.
CANCER (2004)
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
F Saad et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE)
BQ Pan et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
From conventional to stealth liposomes: a new frontier in cancer chemotherapy
L Cattel et al.
JOURNAL OF CHEMOTHERAPY (2004)
Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity
TS Reid et al.
JOURNAL OF MOLECULAR BIOLOGY (2004)
Liposomal alendronate inhibits systemic innate immunity and reduces in-stent neointimal hyperplasia in rabbits
HD Danenberg et al.
CIRCULATION (2003)
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma - A randomized, double-blind, multicenter, comparative trial
LS Rosen et al.
CANCER (2003)
Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer
T Hiraga et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Mode of action of docetaxel - a basis for combination with novel anticancer agents
RS Herbst et al.
CANCER TREATMENT REVIEWS (2003)
Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic
RE Marx
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2003)
γδ T cells for immune therapy of patients with lymphoid malignancies
M Wilhelm et al.
BLOOD (2003)
Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival
PI Croucher et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function
A Skerjanec et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Pharmacokinetics of pegylated liposomal doxorubicin - Review of animal and human studies
A Gabizon et al.
CLINICAL PHARMACOKINETICS (2003)
Uposomally targeted cytotoxic drugs for the treatment of cancer
KJ Harrington et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2002)
Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases
TL Chen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid
J Wood et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
The bisphosphonate zoledronic acid impairs membrane localisation and induces cytochrome c release in breast cancer cells
SG Senaratne et al.
BRITISH JOURNAL OF CANCER (2002)
Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts
V Viereck et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
Metastatic bone disease: clinical features, pathophysiology and treatment strategies
RE Coleman
CANCER TREATMENT REVIEWS (2001)
Share Paper
